Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $2.4 million.

  • Regenxbio's Gains from Investment Securities rose 7236.65% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 164926.32%. This contributed to the annual value of $6.6 million for FY2024, which is 20004.54% up from last year.
  • As of Q3 2025, Regenxbio's Gains from Investment Securities stood at $2.4 million, which was up 7236.65% from -$1.1 million recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Gains from Investment Securities ranged from a high of $9.9 million in Q4 2022 and a low of -$4.5 million during Q2 2023
  • In the last 5 years, Regenxbio's Gains from Investment Securities had a median value of $1.7 million in 2021 and averaged $1.5 million.
  • The largest annual percentage gain for Regenxbio's Gains from Investment Securities in the last 5 years was 527567.57% (2021), contrasted with its biggest fall of 49314.29% (2021).
  • Over the past 5 years, Regenxbio's Gains from Investment Securities (Quarter) stood at $1.6 million in 2021, then surged by 520.45% to $9.9 million in 2022, then crashed by 51.78% to $4.8 million in 2023, then soared by 48.69% to $7.1 million in 2024, then tumbled by 66.31% to $2.4 million in 2025.
  • Its Gains from Investment Securities stands at $2.4 million for Q3 2025, versus -$1.1 million for Q2 2025 and -$1.0 million for Q1 2025.